Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 432

Sort by

Sort Order Select

Journal Articles

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Ana M Hurtado López, Tzu Hua Chen-Liang, María Zurdo, Anna Puiggros, PhD, Andrea Gómez-Llonín, B.Sc., María-Dolores García-Malo, MD, Francisco José Ortuño, Vicente Vicente Garcia, MD PhD, Blanca Espinet, PhD, Andres Jerez

Blood (2019) 134 (Supplement_1): 851.

https://doi.org/10.1182/blood-2019-127960

Published: 2019

Journal Articles

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Thorsten Zenz, MD, Almut Luetge, Junyan Lu, PhD, Huellein Jennifer, PhD, Sascha Dietrich, MD, Leopold Sellner, MD, Wolfgang Huber, PhD

Blood (2019) 134 (Supplement_1): 1742.

https://doi.org/10.1182/blood-2019-126388

Published: 2019

Journal Articles

XPO1 Mutations May Identify Binet Α Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment

Riccardo Moia, MD, Chiara Favini, MSc, Sruthi Sagiraju, Valeria Spina, PhD, Alessio Bruscaggin, PhD, Silvia Rasi, Lorenzo De Paoli, Clara Deambrogi, PhD, Mattia Schipani, Ahad Ahmed Kodipad, Davide Rossi, MD PhD, Gianluca Gaidano, MD PhD

Blood (2019) 134 (Supplement_1): 1743.

https://doi.org/10.1182/blood-2019-126054

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

Impact of Serum Immunoglobulin Subsets and Levels on Chronic Lymphocytic Leukemia Natural History: A Retrospective Multicentric Italian Experience

Luca Laurenti, MD, Andrea Corbingi, MD, Idanna Innocenti, MD PhD, Annamaria Tomasso, Raffaella Pasquale, MD, Andrea Visentin, MD, Marzia Varettoni, Francesco Autore, MD, Francesca Morelli, Livio Trentin, MD, Gianluigi Reda, MD

Blood (2019) 134 (Supplement_1): 3026.

https://doi.org/10.1182/blood-2019-128351

Published: 2019

Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 3035.

https://doi.org/10.1182/blood-2019-123419

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Michele Merli, MD, Benedetta Bianchi, MD, Lorenza Bertù, Andrea Ferrario, MD, Barbara Mora, Silvia Uccella, MD, Daniela Furlan, Maria Grazia Tibiletti, Simona Cattaneo, Fausto Sessa, Prof., Francesco Passamonti, Prof.

Blood (2019) 134 (Supplement_1): 4017.

https://doi.org/10.1182/blood-2019-130288

Published: 2019

Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4312.

https://doi.org/10.1182/blood-2019-122491

Published: 2019

Journal Articles

Next-Generation Optical Mapping Reveals Numerous Previously Unrecognizable Structural Variants in Chronic Lymphocytic Leukemia

Regina Fillerova, PhD, Anna Petrackova, MSc, Tomas Papajik, MD prof, Peter Turcsanyi, MD PhD, Marek Behalek, PhD, Petr Gajdos, PhD assoc prof, Pavlina Ryznerova, MD, Lenka Kruzova, MA, Helena Urbankova, MSc, PhD, Jiri Minarik, MD PhD, Eva Kriegova, Dr, assoc prof

Blood (2019) 134 (Supplement_1): 5450.

https://doi.org/10.1182/blood-2019-127993

Published: 2019

Journal Articles

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

Francesca Arruga, PhD, Giulia Guerra, Denis Baev, PhD, Catherine Hoofd, PhD, Marta Coscia, MD PhD, Giovanni Francesco D'Arena, MD, Gianluca Gaidano, MD PhD, Richard R. Furman, MD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 5454.

https://doi.org/10.1182/blood-2019-128308

Published: 2019

Journal Articles

Chronic Lymphocytic Leukemia in Kuwait

Salem Alshemmari, MDFRCPC, Ramesh Pandita, MD, Abdulaziz Hamadah, MDFRCP(C), Ahmad Alhuraiji, MDMRCP

Blood (2019) 134 (Supplement_1): 5467.

https://doi.org/10.1182/blood-2019-127234

Published: 2019

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Journal Articles

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Shuhua Yi, MD, Yuting Yan, Meiling Jin, Dr., Wenjie Xiong, Zengjun Li, Ying Yu, Rui Cui, MD, Zhen Yu, MD, Yani Lin, Wang Jun, Tingyu Wang, Wei Liu, Kun Ru, MD, Lili Wang, MD PhD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2761.

https://doi.org/10.1182/blood-2019-123194

Published: 2019

Journal Articles

NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia

Stefania Fiorcari, PhD, Rossana Maffei, PhD, Claudio Giacinto Atene, PhD, Silvia Martinelli, Leonardo Potenza, Mario Luppi, MD, Roberto Marasca, MD

Blood (2019) 134 (Supplement_1): 4280.

https://doi.org/10.1182/blood-2019-128499

Published: 2019

Journal Articles

Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections

Pedro Horna, MD, Kathryn E. Pearce, Rhett P. Ketterling, MD, Jess Peterson, MD

Blood (2019) 134 (Supplement_1): 4282.

https://doi.org/10.1182/blood-2019-129116

Published: 2019

Journal Articles

Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18

Agnieszka Malecka, Jan Delabie, MD PhD, Ingunn Ostlie, Anne Tierens, MD PhD, Ulla Randen, MD PhD, Sigbjorn Berentsen, MD PhD, Geir Erland Tjønnfjord, MD PhD, Gunhild Trøen

Blood (2019) 134 (Supplement_1): 1488.

https://doi.org/10.1182/blood-2019-121750

Published: 2019

Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2018-99-110847

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia Patients with IGH Rearrangements Are Characterized By a Distinct Genetic Landscape with Prognostic Implications

Blood (2018) 132 (Supplement 1): 3129.

https://doi.org/10.1182/blood-2018-99-115959

Published: 2018

NARROW

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

XPO1 Mutations May Identify Binet Α Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Impact of Serum Immunoglobulin Subsets and Levels on Chronic Lymphocytic Leukemia Natural History: A Retrospective Multicentric Italian Experience

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Next-Generation Optical Mapping Reveals Numerous Previously Unrecognizable Structural Variants in Chronic Lymphocytic Leukemia

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia in Kuwait

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia

Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections

Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Patients with IGH Rearrangements Are Characterized By a Distinct Genetic Landscape with Prognostic Implications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only